- $20.93bn
- $32.87bn
- $14.30bn
What to Watch in the Day Ahead - Thursday, February 26
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Viatris rises as FDA begins review of eye drop for age‑related near‑vision loss
Brief: FDA Accepts Viatris Supplemental New Drug Application For Mr-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia
Brief: Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade
Brief: Viatris Appoints Lara Ramsburg As Chief People And Corporate Affairs Officer
US FDA approves Vanda Pharmaceuticals' motion sickness drug (updated)
US FDA approves Vanda Pharmaceuticals' motion sickness drug
Brief: Viatris Provides Pipeline Update On Four Regulatory Milestones
Biocon fully integrates Biocon Biologics in $5.5 billion deal (updated)
India's Biocon to make Biocon Biologics a wholly owned subsidiary (updated)
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade
Brief: EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade
Viagra-maker Viatris beats quarterly estimates on strong demand for branded drugs (updated)